The insomnia market size has grown strongly in recent years. It will grow from $4.72 billion in 2023 to $4.97 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth observed in the historical period can be attributed to factors such as increased stress levels, the prevalence of mental health conditions, shift work and irregular work hours, increased awareness and diagnosis of insomnia, and high consumption of stimulants.
The insomnia market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period can be attributed to the impact of the global health crisis, an increasing awareness of sleep hygiene, a growing emphasis on mental health and wellness, government initiatives for sleep health, and the influence of social determinants on sleep. Major trends expected in the forecast period include the adoption of digital health solutions for sleep monitoring, the implementation of cognitive-behavioral therapy for insomnia, the use of telehealth for sleep consultations, the integration of sleep health into primary care, and ongoing research on novel therapeutic targets for insomnia treatment.
The insomnia market is expected to experience growth due to the surge in work-related stress. Work-related stress refers to harmful emotional and physical responses resulting from a mismatch between work demands, pressures, and the worker's resources, capabilities, or knowledge. Job stress can lead to poor health, including insomnia. The severity of insomnia determines the treatment approach, which may involve drug or cognitive-behavioral therapies. The insomnia market is witnessing increased sales due to the rise in work-related stress. For instance, a survey by the American Psychology Association in October 2021 revealed that about 59% of 1,500 US employees were experiencing work-related stress. Additionally, according to the US Bureau of Labor Statistics in November 2022, the total rate of injuries increased in 2021, with reported injuries rising by 6.3% compared to 2020. This surge in work-related stress is a significant driver of the insomnia market.
The growth of the insomnia market is also expected to be propelled by the increasing prevalence of chronic diseases. Chronic diseases, lasting for three months or more and worsening over time, often lead to comorbid conditions such as insomnia. Individuals with chronic conditions such as cardiovascular disorders, diabetes, and chronic pain frequently experience sleep-related issues. The rising prevalence of chronic diseases creates a demand for effective insomnia treatments and management strategies, contributing to the growth of the market. According to the National Center for Biotechnology Information in January 2023, the global number of people with chronic diseases is projected to reach 142.66 million by 2050, up from 71.522 million in 2020. Therefore, the increasing prevalence of chronic diseases is a significant factor driving the growth of the insomnia market.
A key trend in the insomnia market is the adoption of product innovation. Major companies in the insomnia therapeutics market are developing innovative treatments to maintain their market positions. For example, WELT, a Korea-based medical device company, received approval for its digital insomnia treatment device, WELT-I, in April 2023. WELT-I is designed to correct behavioral, psychological, and cognitive factors contributing to insomnia. It delivers treatment based on cognitive behavioral therapy (CBT), a first-line treatment for insomnia. The device, classified as software as a medical device (SaMD), analyzes sleep patterns, intervenes in patient behavior, and delivers personalized relaxation therapy for eight weeks to improve sleep quality and reduce tension and anxiety.
Major companies in the insomnia market are introducing new products, such as zaleplon-based insomnia drugs, to gain a competitive edge. Zaleplon, a non-benzodiazepine sedative-hypnotic medication, is used for the short-term treatment of insomnia. For instance, in April 2023, Bukwang Pharm Co Ltd., a South Korea-based pharmaceutical company, launched Zaledeep Cap., the first insomnia treatment in South Korea utilizing zaleplon as its main ingredient. Zaleplon is known for its rapid onset of action, short half-life, and minimal impact on daily activities. The launch of Zaledeep Cap. aims to provide a new and effective treatment option for individuals suffering from insomnia in response to the increasing cases in modern society.
In August 2022, ResMed, a US-based medical equipment company, acquired Mementor to strengthen its sleep portfolio in Germany. This acquisition included somnio, a digital solution for insomnia, Germany's first and only permanently approved digital health application (DiGA) in sleep medicine. Somnio focuses on improving sleep in insomnia patients, addressing the care gap, and providing alternatives to prevailing drug therapy. Mementor, a Germany-based developer of digital insomnia therapy solutions, contributes to ResMed's overall commitment to enhancing sleep-related healthcare.
Major companies operating in the insomnia market report are Pfizer Inc., Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Viatris Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Eisai Co.Ltd., UCLA Health Insomnia Clinic, Jazz Pharmaceuticals PLC, Aurobindo Pharma Limited, Purdue Pharma LP, Cipla Inc., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Lupin Limited, Mallinckrodt Pharmaceuticals Plc., Fisher & Paykel Healthcare Corporation Limited, ResMed Inc., Sunovion Pharmaceuticals Inc., Casper Sleep Inc., Biocodex Inc., Vanda Pharmaceuticals Inc., Pernix Therapeutics Holdings Inc., SleepScore Labs, Alpha-Stim, Neurim Pharmaceuticals Ltd., NightWare Inc.
North America was the largest region in the insomnia market in 2023. The regions covered in the insomnia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insomnia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main therapy types for insomnia encompass non-pharmacological therapy and pharmacological therapy. Non-pharmacological interventions (NPI) or non-pharmacological therapies involve non-chemical interventions performed on and benefiting the patient, such as light therapy and exercise. The various drug classes utilized in pharmacological therapy include anti-depressants, melatonin antagonists, benzodiazepines, non-benzodiazepines, orexin antagonists, and others. These drugs are administered through various routes, such as oral and parenteral, and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The insomnia market research report is one of a series of new reports that provides insomnia market statistics, including insomnia industry global market size, regional shares, competitors with an insomnia market share, detailed insomnia market segments, market trends, and opportunities, and any further data you may need to thrive in the insomnia industry. This insomnia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The insomnia market consists of revenues earned by entities by providing therapies such as light therapy, stimulus control therapy, and relaxation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The insomnia market also includes sales of triazolam, estazolam, temazepam, quazepam, and flurazepam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The insomnia market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period can be attributed to the impact of the global health crisis, an increasing awareness of sleep hygiene, a growing emphasis on mental health and wellness, government initiatives for sleep health, and the influence of social determinants on sleep. Major trends expected in the forecast period include the adoption of digital health solutions for sleep monitoring, the implementation of cognitive-behavioral therapy for insomnia, the use of telehealth for sleep consultations, the integration of sleep health into primary care, and ongoing research on novel therapeutic targets for insomnia treatment.
The insomnia market is expected to experience growth due to the surge in work-related stress. Work-related stress refers to harmful emotional and physical responses resulting from a mismatch between work demands, pressures, and the worker's resources, capabilities, or knowledge. Job stress can lead to poor health, including insomnia. The severity of insomnia determines the treatment approach, which may involve drug or cognitive-behavioral therapies. The insomnia market is witnessing increased sales due to the rise in work-related stress. For instance, a survey by the American Psychology Association in October 2021 revealed that about 59% of 1,500 US employees were experiencing work-related stress. Additionally, according to the US Bureau of Labor Statistics in November 2022, the total rate of injuries increased in 2021, with reported injuries rising by 6.3% compared to 2020. This surge in work-related stress is a significant driver of the insomnia market.
The growth of the insomnia market is also expected to be propelled by the increasing prevalence of chronic diseases. Chronic diseases, lasting for three months or more and worsening over time, often lead to comorbid conditions such as insomnia. Individuals with chronic conditions such as cardiovascular disorders, diabetes, and chronic pain frequently experience sleep-related issues. The rising prevalence of chronic diseases creates a demand for effective insomnia treatments and management strategies, contributing to the growth of the market. According to the National Center for Biotechnology Information in January 2023, the global number of people with chronic diseases is projected to reach 142.66 million by 2050, up from 71.522 million in 2020. Therefore, the increasing prevalence of chronic diseases is a significant factor driving the growth of the insomnia market.
A key trend in the insomnia market is the adoption of product innovation. Major companies in the insomnia therapeutics market are developing innovative treatments to maintain their market positions. For example, WELT, a Korea-based medical device company, received approval for its digital insomnia treatment device, WELT-I, in April 2023. WELT-I is designed to correct behavioral, psychological, and cognitive factors contributing to insomnia. It delivers treatment based on cognitive behavioral therapy (CBT), a first-line treatment for insomnia. The device, classified as software as a medical device (SaMD), analyzes sleep patterns, intervenes in patient behavior, and delivers personalized relaxation therapy for eight weeks to improve sleep quality and reduce tension and anxiety.
Major companies in the insomnia market are introducing new products, such as zaleplon-based insomnia drugs, to gain a competitive edge. Zaleplon, a non-benzodiazepine sedative-hypnotic medication, is used for the short-term treatment of insomnia. For instance, in April 2023, Bukwang Pharm Co Ltd., a South Korea-based pharmaceutical company, launched Zaledeep Cap., the first insomnia treatment in South Korea utilizing zaleplon as its main ingredient. Zaleplon is known for its rapid onset of action, short half-life, and minimal impact on daily activities. The launch of Zaledeep Cap. aims to provide a new and effective treatment option for individuals suffering from insomnia in response to the increasing cases in modern society.
In August 2022, ResMed, a US-based medical equipment company, acquired Mementor to strengthen its sleep portfolio in Germany. This acquisition included somnio, a digital solution for insomnia, Germany's first and only permanently approved digital health application (DiGA) in sleep medicine. Somnio focuses on improving sleep in insomnia patients, addressing the care gap, and providing alternatives to prevailing drug therapy. Mementor, a Germany-based developer of digital insomnia therapy solutions, contributes to ResMed's overall commitment to enhancing sleep-related healthcare.
Major companies operating in the insomnia market report are Pfizer Inc., Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Viatris Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Eisai Co.Ltd., UCLA Health Insomnia Clinic, Jazz Pharmaceuticals PLC, Aurobindo Pharma Limited, Purdue Pharma LP, Cipla Inc., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Lupin Limited, Mallinckrodt Pharmaceuticals Plc., Fisher & Paykel Healthcare Corporation Limited, ResMed Inc., Sunovion Pharmaceuticals Inc., Casper Sleep Inc., Biocodex Inc., Vanda Pharmaceuticals Inc., Pernix Therapeutics Holdings Inc., SleepScore Labs, Alpha-Stim, Neurim Pharmaceuticals Ltd., NightWare Inc.
North America was the largest region in the insomnia market in 2023. The regions covered in the insomnia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insomnia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main therapy types for insomnia encompass non-pharmacological therapy and pharmacological therapy. Non-pharmacological interventions (NPI) or non-pharmacological therapies involve non-chemical interventions performed on and benefiting the patient, such as light therapy and exercise. The various drug classes utilized in pharmacological therapy include anti-depressants, melatonin antagonists, benzodiazepines, non-benzodiazepines, orexin antagonists, and others. These drugs are administered through various routes, such as oral and parenteral, and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The insomnia market research report is one of a series of new reports that provides insomnia market statistics, including insomnia industry global market size, regional shares, competitors with an insomnia market share, detailed insomnia market segments, market trends, and opportunities, and any further data you may need to thrive in the insomnia industry. This insomnia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The insomnia market consists of revenues earned by entities by providing therapies such as light therapy, stimulus control therapy, and relaxation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The insomnia market also includes sales of triazolam, estazolam, temazepam, quazepam, and flurazepam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Insomnia Market Characteristics3. Insomnia Market Trends and Strategies32. Global Insomnia Market Competitive Benchmarking33. Global Insomnia Market Competitive Dashboard34. Key Mergers and Acquisitions in the Insomnia Market
4. Insomnia Market - Macro Economic Scenario
5. Global Insomnia Market Size and Growth
6. Insomnia Market Segmentation
7. Insomnia Market Regional and Country Analysis
8. Asia-Pacific Insomnia Market
9. China Insomnia Market
10. India Insomnia Market
11. Japan Insomnia Market
12. Australia Insomnia Market
13. Indonesia Insomnia Market
14. South Korea Insomnia Market
15. Western Europe Insomnia Market
16. UK Insomnia Market
17. Germany Insomnia Market
18. France Insomnia Market
19. Italy Insomnia Market
20. Spain Insomnia Market
21. Eastern Europe Insomnia Market
22. Russia Insomnia Market
23. North America Insomnia Market
24. USA Insomnia Market
25. Canada Insomnia Market
26. South America Insomnia Market
27. Brazil Insomnia Market
28. Middle East Insomnia Market
29. Africa Insomnia Market
30. Insomnia Market Competitive Landscape and Company Profiles
31. Insomnia Market Other Major and Innovative Companies
35. Insomnia Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Insomnia Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on insomnia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for insomnia? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Therapy Type: Non-Pharmacological Therapy; Pharmacological Therapy
2) By Drug Class: Anti-Depressants; Melatonin Antagonist; Benzodiazepines; Nonbenzodiazepines; Orexin Antagonist; Other Drug Classes
3) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Key Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Sanofi S.A.; GlaxoSmithKline plc.; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- Merck & Co Inc.
- Sanofi S.A.
- GlaxoSmithKline plc.
- Takeda Pharmaceutical Company Limited
- Koninklijke Philips N.V.
- Viatris Inc.
- Astellas Pharma Inc.
- Sun Pharmaceutical Industries Limited
- Eisai Co.Ltd.
- UCLA Health Insomnia Clinic
- Jazz Pharmaceuticals PLC
- Aurobindo Pharma Limited
- Purdue Pharma LP
- Cipla Inc.
- Dr. Reddy's Laboratories Ltd.
- Zydus Lifesciences Limited
- Lupin Limited
- Mallinckrodt Pharmaceuticals Plc.
- Fisher & Paykel Healthcare Corporation Limited
- ResMed Inc.
- Sunovion Pharmaceuticals Inc.
- Casper Sleep Inc.
- Biocodex Inc.
- Vanda Pharmaceuticals Inc.
- Pernix Therapeutics Holdings Inc.
- SleepScore Labs
- Alpha-Stim
- Neurim Pharmaceuticals Ltd.
- NightWare Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 4.97 Billion |
| Forecasted Market Value ( USD | $ 6.09 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
